| Literature DB >> 30123328 |
Soraya Hengsawas Surasarang1, Sawittree Sahakijpijarn1, Galina Florova2, Andrey A Komissarov2, Christina L Nelson3, Enkhbaatar Perenlei3, Satoshi Fukuda3, Marla R Wolfson4, Thomas H Shaffer4,5, Steven Idell2, Robert O Williams1.
Abstract
Single-chain tissue-type plasminogen activator (sctPA) and single-chain urokinase plasminogen activator (scuPA) have attracted interest as enzymes for the treatment of inhalational smoke-induced acute lung injury (ISALI). In this study, the pulmonary delivery of commercial human sctPA and lyophilized scuPA and their reconstituted solution forms were demonstrated using vibrating mesh nebulizers (Aeroneb® Pro (active) and EZ Breathe® (passive)). Both the Aeroneb® Pro and EZ Breathe® vibrating mesh nebulizers produced atomized droplets of protein solution of similar size of less than about 5 μm, which is appropriate for pulmonary delivery. Enzymatic activities of scuPA and of sctPA were determined after nebulization and both remained stable (88.0% and 93.9%). Additionally, the enzymatic activities of sctPA and tcuPA were not significantly affected by excipients, lyophilization or reconstitution conditions. The results of these studies support further development of inhaled formulations of fibrinolysins for delivery to the lungs following smoke-induced acute pulmonary injury.Entities:
Keywords: Single-chain tissue-type plasminogen activator; inhalational smoke-induced acute lung injury; lyophilization; nebulization; pulmonary delivery; single-chain urokinase plasminogen activator; vibrating mesh nebulizers
Year: 2018 PMID: 30123328 PMCID: PMC6095669 DOI: 10.1016/j.jddst.2018.04.013
Source DB: PubMed Journal: J Drug Deliv Sci Technol ISSN: 1773-2247 Impact factor: 3.981